Aslan Pharmaceuticals Ltd at Needham Healthcare Conference (Virtual) Transcript
Hi, good morning. Welcome to Needham's annual 21st healthcare conference. I'm Serge Belanger, one of the healthcare analysts at Needham. And we are happy to have this morning ASLAN Pharmaceuticals, a clinical-stage dermatology company, with an asset under development in atopic dermatitis. We have the company CEO, Carl Firth, with us and he's going to give us an overview. (Conference Instructions)
So I'll hand it over to Carl, and he can give us an overview of ASLAN. Carl?
Thank you very much, Serge. Thank you for the introduction. It's a real pleasure to be here today at the Needham conference, and I'd like to take you through a brief introduction to our company. First of all, I'd just like to draw your attention to the forward-looking statements here and some of the risk statements that's posted on the SEC website.
So by way of overview, ASLAN is a company that's targeting immunology conditions, in particular, inflammatory disease markets,
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
